A biomarker framework for liver aging: the Aging Biomarker Consortium consensus statement

Abstract

In human aging, liver aging per se not only increases susceptibility to liver diseases but also increases vulnerability of other organs given its central role in regulating metabolism. Total liver function tends to be well maintained in the healthy elderly, so liver aging is generally difficult to identify early. In response to this critical challenge, the Aging Biomarker Consortium of China has formulated an expert consensus on biomarkers of liver aging by synthesizing the latest scientific literature, comprising insights from both scientists and clinicians. This consensus provides a comprehensive assessment of biomarkers associated with liver aging and presents a systematic framework to characterize these into three dimensions: functional, imaging, and humoral. For the functional domain, we highlight biomarkers associated with cholesterol metabolism and liver-related coagulation function. For the imaging domain, we note that hepatic steatosis and liver blood flow can serve as measurable biomarkers for liver aging. Finally, in the humoral domain, we pinpoint hepatokines and enzymatic alterations worthy of attention. The aim of this expert consensus is to establish a foundation for assessing the extent of liver aging and identify early signs of liver aging-related diseases, thereby improving liver health and the healthy life expectancy of the elderly population.

References

[1] Ma S, Chi X, Cai Y, et al. Decoding aging hallmarks at the single-cell level. Ann Rev Biomed Data Sci 2023;6:129–52.

[2] Wu Z, Qu J, Zhang W, et al. Stress, epigenetics, and aging: unraveling the intricate crosstalk. Mol Cell 2023;84:34–54.

[3] Heinke P, Rost F, Rode J, et al. Diploid hepatocytes drive physiological liver renewal in adult humans. Cell Syst 2022;13:499–507.e12.

[4] Hunt NJ, Kang SW, Lockwood GP, et al. Hallmarks of aging in the liver. Comput Struct Biotechnol J 2019;17:1151–61.

[5] Kim IH, Kisseleva T, Brenner DA. Aging and liver disease. Curr Opin Gastroenterol 2015;31:184–91.

[6] Carrier P, Debette-Gratien M, Jacques J, et al. Cirrhotic patients and older people. World J Hepatol 2019;11:663–77.

[7] Macias RIR, Monte MJ, Serrano MA, et al. Impact of aging on primary liver cancer: epidemiology, pathogenesis and therapeutics. Aging (Albany NY) 2021;13:23416–34.

[8] Gmizić T, Dukić M, Jovanović I, et al. Aging of liver in its different diseases. Int J Mol Sci 2022;23:13085.

[9] Johnson SR, Alexopoulos S, Curry M, et al. Primary nonfunction (PNF) in the MELD Era: an SRTR database analysis. Am J Transplant 2007;7:1003–9.

[10] Detre KM, Lombardero M, Belle S, et al. Influence of donor age on graft survival after liver transplantation—United Network for Organ Sharing Registry. Liver Transpl Surg 1995;1:311–9.

[11] Wu Y, Dong J-H, Dai Y-F, et al. Hepatic soluble epoxide hydrolase activity regulates cerebral Aβ metabolism and the pathogenesis of Alzheimer’s disease in mice. Neuron 2023;111:2847–62.

[12] Gee LMV, Barron-Millar B, Leslie J, et al. Anti–Cholestatic Therapy with obeticholic acid improves short-term memory in bile duct–ligated mice. Am J Pathol 2023;193:11–26.

[13] Lu K, Shi TS, Shen SY, et al. Defects in a liver-bone axis contribute to hepatic osteodystrophy disease progression. Cell Metab 2022;34:441–457.e7.

[14] Lin LS, Guo ZY, He EJ, et al. SIRT2 regulates extracellular vesicle-mediated liver-bone communication. Nat Metab 2023;5:821–41.

[15] Jensen-Cody SO, Potthoff MJ. Hepatokines and metabolism: deciphering communication from the liver. Mol Metab 2021;44:101138.

[16] Peng Y, Ding L, Song M, et al. Acting on ethics and governance of aging research. Trends Mol Med 2023;29:419–21.

[17] Collaborators GBD, Ärnlöv J. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. Lancet 2020;396:1160–203.

[18] Suo J, Gan Y, Yangli X et al.; Aging Biomarker Consortium. A framework of biomarkers for skeletal aging: a consensus statement by the Aging Biomarker Consortium. Life Med 2023;2:lnad045.

[19] Cai Y, Song W, Li J, et al. The landscape of aging. Sci China Life Sci 2022;65:2354–454.

[20] Bao H, Cao J, Chen M, et al; Aging Biomarker Consortium. Biomarkers of aging. Sci China Life Sci 2023;66:893–1066.

[21] Zhang L, Guo J et al.; Aging Biomarker Consortium. A framework of biomarkers for vascular aging: a consensus statement by the Aging Biomarker Consortium. Life Med 2023;2:lnad033.

[22] Jia Y-J, Wang J, Ren J-R et al.; Aging Biomarker Consortium. A framework of biomarkers for brain aging: a consensus statement by the Aging Biomarker Consortium. Life Med 2023;2:lnad017.

[23] Zhang W, Che Y, Tang X et al.; Aging Biomarker Consortium. A biomarker framework for cardiac aging: the Aging Biomarker Consortium consensus statement. Life Med 2023;2:lnad035.

[24] Ren J, Song M, Zhang W, et al. The Aging Biomarker Consortium represents a new era for aging research in China. Nat Med 2023;29:2162–5.

[25] Sousa-Uva M, Head SJ, Thielmann M, et al. Methodology manual for European Association for Cardio-Thoracic Surgery (EACTS) clinical guidelines. Eur J Cardiothorac Surg 2015;48:ezv309–16.

[26] Taub R. Liver regeneration: from myth to mechanism. Nat Rev Mol Cell Biol 2004;5:836–47.

[27] Jiang M, Ren J, Izpisua Belmonte JC, et al. Hepatocyte reprogramming in liver regeneration: biological mechanisms and applications. FEBS J 2023;290:5674–88.

[28] Miyaoka Y, Ebato K, Kato H, et al. Hypertrophy and unconventional cell division of hepatocytes underlie liver regeneration. Curr Biol 2012;22:1166–75.

[29] Kodavanti PR, Joshi UM, Young RA, et al. Protection of hepatotoxic and lethal effects of CCl4 by partial hepatectomy. Toxicol Pathol 1989;17:494–505.

[30] Shirabe K, Motomura T, Takeishi K, et al. Human early liver regeneration after hepatectomy in patients with hepatocellular carcinoma: special reference to age. Scand J Surg 2013;102:101–5.

[31] Zhu CZ, Ikemoto T, Utsunomiya T, et al. Senescence-related genes possibly responsible for poor liver regeneration after hepatectomy in elderly patients. J Gastroen Hepatol 2014;29:1102–8.

[32] Inoue Y, Tanaka R, Fujii K, et al. Surgical outcome and hepatic regeneration after hepatic resection for hepatocellular carcinoma in elderly patients. Digest Surg 2019;36:289–301.

[33] Yasuda S, Nomi T, Hokuto D, et al. Liver regeneration after major liver resection for hepatocellular carcinoma in the elderly. J Invest Surg 2020;33:332–8.

[34] Fernandes AI, Tralhao JG, Abrantes A, et al. Functional hepatocellular regeneration in elderly patients undergoing hepatectomy. Liver Int 2015;35:1116–23.

[35] Fry M, Silber J, Loeb LA, et al. Delayed and reduced cell replication and diminishing levels of DNA polymerase-alpha in regenerating liver of aging mice. J Cell Physiol 1984;118:225–32.

[36] Tsukamoto I, Nakata R, Kojo S. Effect of aging on rat-liver regeneration after partial-hepatectomy. Biochem Mol Biol Int 1993;30:773–8.

[37] Sanz N, Diez-Fernandez C, Alvarez AM, et al. Age-related changes on parameters of experimentally-induced liver injury and regeneration. Toxicol Appl Pharm 1999;154:40–9.

[38] Biondo-Simoes MDEL, Matias JE, Montibeller GR, et al. Effect of aging on liver regeneration in rats. Acta Cir Bras 2006;21:197–202.

[39] Gagliano N, Grizzi F, Annoni G. Mechanisms of aging and liver functions. Digest Dis 2007;25:118–23.

[40] Feng S, Goodrich NP, Bragg-Gresham JL, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006;6:783–90.

[41] Braat AE, Blok JJ, Putter H, et al; European Liver and Intestine Transplant Association (ELITA) and Eurotransplant Liver Intestine Advisory Committee (ELIAC). The Eurotransplant Donor Risk Index in Liver Transplantation: ET-DRI. Am J Transplant 2012;12:2789–96.

[42] Akamatsu N, Sugawara Y, Tamura S, et al. Impact of live donor age (>= 50) on liver transplantation. Transpl Proc 2007;39:3189–93.

[43] Wang MJ, Chen F, Lau JTY, et al. Hepatocyte polyploidization and its association with pathophysiological processes. Cell Death Dis 2017;8:e2805.

[44] Kim JY, Choi H, Kim HJ, et al. Polyploidization of hepatocytes: insights into the pathogenesis of liver diseases. Biomol Ther 2022;30:391–8.

[45] Maeso-Diaz R, Gracia-Sancho J. Aging and chronic liver disease. Semin Liver Dis 2020;40:373–84.

[46] Hoare M, Das T, Alexander G. Ageing, telomeres, senescence, and liver injury. J Hepatol 2010;53:950–61.

[47] Timchenko NA. Aging and liver regeneration. Trends Endocrinol Metab 2009;20:171–6.

[48] Wang MJ, Chen F, Li JX, et al. Reversal of hepatocyte senescence after continuous in vivo cell proliferation. Hepatology 2014;60:349–61.

[49] Enkhbold C, Morine Y, Utsunomiya T, et al. Dysfunction of liver regeneration in aged liver after partial hepatectomy. J Gastroenterol Hepatol 2015;30:1217–24.

[50] Bellanti F, Vendemiale G. The aging liver: redox biology and liver regeneration. Antioxid Redox Signal 2021;35:832–47.

[51] Chen YH, Chen LL, Wu XS, et al. Acute liver steatosis translationally controls the epigenetic regulator MIER1 to promote liver regeneration in a study with male mice. Nat Commun 2023;14:1521.

[52] Sawada N. Hepatocytes from old rats retain responsiveness of c-myc expression to EGF in primary culture but do not enter S phase. Exp Cell Res 1989;181:584–8.

[53] Marti U. Handling of epidermal growth-factor and number of epidermal growth-factor receptors are changed in aged male-rats. Hepatology 1993;18:1432–6.

[54] Mclachlan AJ, Pont LG. Drug metabolism in older people—a key consideration in achieving optimal outcomes with medicines. J Gerontol Biol Sci 2012;67:175–80.

[55] Mclean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev 2004;56:163–84.

[56] Butler JM, Begg EJ. Free drug metabolic clearance in elderly people. Clin Pharmacokinet 2008;47:297–321.

[57] Woodhouse KW, Wynne HA. Age-related-changes in liver size and hepatic blood-flow—the influence on drug-metabolism in the elderly. Clin Pharmacokinet 1988;15:287–94.

[58] Bao HN, Cao JN, Chen MT, et al. Biomarkers of aging. Sci China Life Sci 2023;66:893–1066.

[59] Schmucker DL. Liver function and phase I drug metabolism in the elderly—a paradox. Drug Aging 2001;18:837–51.

[60] Parkinson A, Mudra DR, Johnson C, et al. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharm 2004;199:193–209.

[61] Wynne H. Drug metabolism and ageing. J Br Menopause Soc 2005;11:51–6.

[62] Sotaniemi EA, Arranto AJ, Pelkonen O, et al. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther 1997;61:331–9.

[63] Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 2009;41:67–76.

[64] Mclean AJ, Cogger VC, Chong GC, et al. Age-related pseudocapillarization of the human liver. J Pathol 2003;200:112–7.

[65] Simon-Santamaria J, Malovic I, Warren A, et al. Age-related changes in scavenger receptor-mediated endocytosis in rat liver sinusoidal endothelial cells. J Gerontol Biol Sci 2010;65:951–60.

[66] Wan Y, Li X, Slevin E, et al. Endothelial dysfunction in pathological processes of chronic liver disease during aging. FASEB J 2022;36:e22125.

[67] Hunt NJ, Mccourt PAG, Le Couteur DG, et al. Novel targets for delaying aging: the importance of the liver and advances in drug delivery. Adv Drug Deliv Rev 2018;135:39–49.

[68] Le Couteur DG, Cogger VC, markus AM, et al. Pseudocapillarization and associated energy limitation in the aged rat liver. Hepatology 2001;33:537–43.

[69] Le Couteur DG, Fraser R, Hilmer S, et al. The hepatic sinusoid in aging and cirrhosis—effects on hepatic substrate disposition and drug clearance. Clin Pharmacokinet 2005;44:187–200.

[70] Kagansky N, Levy S, Keter D, et al. Non-alcoholic fatty liver disease— a common and benign finding in octogenarian patients. Liver Int 2004;24:588–94.

[71] Frith J, Day CP, Henderson E, et al. Non-alcoholic fatty liver disease in older people. Gerontology 2009;55:607–13.

[72] Noureddin M, Yates KP, Vaughn IA, et al; NASH CRN. Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology 2013;58:1644–54.

[73] Hartleb M, Baranski K, Zejda J, et al. Non-alcoholic fatty liver and advanced fibrosis in the elderly: results from a community-based Polish survey. Liver Int 2017;37:1706–14.

[74] Chen TP, Lai M, Lin WY, et al. Metabolic profiles and fibrosis of nonalcoholic fatty liver disease in the elderly: a community-based study. J Gastroenterol Hepatol 2020;35:1636–43.

[75] Chung KW. Advances in understanding of the role of lipid metabolism in aging. Cells-Basel 2021;10:880.

[76] Tietz NW, Shuey DF, Wekstein DR. Laboratory values in fit aging individuals—sexagenarians through centenarians. Clin Chem 1992;38:1167–85.

[77] Woudstra TD, Drozdowski LA, Wild GE, et al. The age-related decline in intestinal lipid uptake is associated with a reduced abundance of fatty acid-binding protein. Lipids 2004;39:603–10.

[78] Sheedfar F, Sung MMY, Aparicio-Vergara M, et al. Increased hepatic CD36 expression with age is associated with enhanced susceptibility to nonalcoholic fatty liver disease. Aging-Us 2014;6:281–95.

[79] Porukala M, Vinod PK. Network-level analysis of ageing and its relationship with diseases and tissue regeneration in the mouse liver. Sci Rep 2023;13:4632.

[80] Lv J, Hu YM, Li LL, et al. Targeting FABP4 in elderly mice rejuvenates liver metabolism and ameliorates aging-associated metabolic disorders. Metabolism 2023;142:155528.

[81] Kim YM, Shin HT, Seo YH, et al. Sterol Regulatory Element-binding Protein (SREBP)-1-mediated lipogenesis is involved in cell senescence. J Biol Chem 2010;285:29069–77.

[82] Salamanca A, Barcena B, Arribas C, et al. Aging impairs the hepatic subcellular distribution of ChREBP in response to fasting/feeding in rats: implications on hepatic steatosis. Exp Gerontol 2015;69:9–19.

[83] Iizuka K, Bruick RK, Liang G, et al. Deficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis. Proc Natl Acad Sci USA 2004;101:7281–6.

[84] Ogrodnik M, Miwa S, Tchkonia T, et al. Cellular senescence drives age-dependent hepatic steatosis. Nat Commun 2017;8:15691.

[85] Repa JJ, Mangelsdorf DJ. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu Rev Cell Dev Biol 2000;16:459–81.

[86] Gylling H. Cholesterol metabolism and its implications for therapeutic interventions in patients with hypercholesterolaemia. Int J Clin Pract 2004;58:859–66.

[87] Bertolotti M, Mussi C, Pellegrini E, et al. Age-associated alterations in cholesterol homeostasis: evidence from a cross-sectional study in a Northern Italy population. Clin Interv Aging 2014;9:425–32.

[88] Duan LP, Wang HH, Ohashi A, et al. Role of intestinal sterol transporters Abcg5, Abcg8, and Npc1l1 in cholesterol absorption in mice: gender and age effects. Am J Physiol Gastrointest Liver Physiol 2006;290:G269–76.

[89] Mulas MF, Demuro G, Mulas C, et al. Dietary restriction counteracts age-related changes in cholesterol metabolism in the rat. Mech Ageing Dev 2005;126:648–54.

[90] Seo E, Kang H, Choi H, et al. Reactive oxygen species-induced changes in glucose and lipid metabolism contribute to the accumulation of cholesterol in the liver during aging. Aging Cell 2019;18:e12895.

[91] Yang S, Liu C, Jiang M, et al. A single-nucleus transcriptomic atlas of primate liver aging uncovers the pro-senescence role of SREBP2 in hepatocytes. Protein Cell 2023;15:98–120.

[92] Heinze I, Bens M, Calzia E, et al. Species comparison of liver proteomes reveals links to naked mole-rat longevity and human aging. BMC Biol 2018;16:82.

[93] Abbott RD, Garrison RJ, Wilson PWF, et al. Joint distribution of lipoprotein cholesterol classes—the Framingham-Study. Arteriosclerosis 1983;3:260–72.

[94] Veniant MM, Zlot CH, Walzem RL, et al. Lipoprotein clearance mechanisms in LDL receptor-deficient “Apo-B48-only” and “Apo-B100-only” mice. J Clin Invest 1998;102:1559–68.

[95] Go GW, Mani A. Low-density lipoprotein receptor (LDLR) family orchestrates cholesterol homeostasis. Yale J Biol Med 2012;85:19–28.

[96] Millar JS, Lichtenstein AH, Cuchel M, et al. Impact of age on the metabolism of Vldl, Idl, and Ldl Apolipoprotein B-100 in men. J Lipid Res 1995;36:1155–67.

[97] Zhang DW, Lagace TA, Garuti R, et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat a of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem 2007;282:18602–12.

[98] Cui Q, Ju XX, Yang T, et al. Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population. Atherosclerosis 2010;213:632–6.

[99] Einarsson K, Nilsell K, Leijd B, et al. Influence of age on secretion of cholesterol and synthesis of bile-acids by the liver. New Engl J Med 1985;313:277–82.

[100] Bertolotti M, Gabbi C, Anzivino C, et al. Age-related changes in bile acid synthesis and hepatic nuclear receptor expression. Eur J Clin Invest 2007;37:501–8.

[101] Bertolotti M, Abate N, Bertolotti S, et al. Effect of aging on cholesterol 7-Alpha-Hydroxylation in humans. J Lipid Res 1993;34:1001–7.

[102] Chia CW, Egan JM, Ferrucci L. Age-related changes in glucose metabolism, hyperglycemia, and cardiovascular risk. Circ Res 2018;123:886–904.

[103] Muller DC, Elahi D, Tobin JD, et al. Insulin response during the oral glucose tolerance test: the role of age, sex, body fat and the pattern of fat distribution. Aging 1996;8:13–21.

[104] Natali A, Toschi E, Camastra S, et al. Determinants of postabsorptive endogenous glucose output in non-diabetic subjects. Diabetologia 2000;43:1266–72.

[105] Zavaroni I, Dallaglio E, Bruschi F, et al. Effect of age and environmental-factors on glucose-tolerance and insulin-secretion in a worker population. J Am Geriatr Soc 1986;34:271–5.

[106] Shimokata H, Muller DC, Fleg JL, et al. Age as independent determinant of glucose-tolerance. Diabetes 1991;40:44–51.

[107] Zamboni M, Armellini F, Harris T, et al. Effects of age on body fat distribution and cardiovascular risk factors in women. Am J Clin Nutr 1997;66:111–5.

[108] Amin H, Mohsin S, Aslam M, et al. Coagulation factors and antithrombin levels in young and elderly subjects in Pakistani population. Blood Coagul Fibrin 2012;23:745–50.

[109] Franchini M. Hemostasis and aging. Crit Rev Oncol Hemat 2006;60:144–51.

[110] Kannel WB, Wolf PA, Castelli WP, et al. Fibrinogen and risk of cardiovascular-disease—the Framingham-Study. Jama-J Am Med Assoc 1987;258:1183–6.

[111] Meade TW, North WR, Chakrabarti R, et al. Population-based distributions of haemostatic variables. Br Med Bull 1977;33:283–8.

[112] Mari D, Coppola R, Provenzano R. Hemostasis factors and aging. Exp Gerontol 2008;43:66–73.

[113] Pajak A, Broda G, Manolio TA, et al. Constitutional, biochemical and lifestyle correlates of fibrinogen and factor VII activity in Polish urban and rural populations. Int J Epidemiol 1998;27:953–61.

[114] Scarabin PY, Vissac AM, Kirzin JM, et al. Population correlates of coagulation factor VII—Importance of age, sex, and menopausal status as determinants of activated factor VII. Arterioscl Throm Vas 1996;16:1170–6.

[115] Vohra V. Coagulation in liver disease. In: Vohra V, Gupta N, Jolly AS, et al. Peri-operative Anesthetic Management in Liver Transplantation. Singapore: Springer Nature Singapore, 2023, 163–76.

[116] Lowe GD, Rumley A, Woodward M, et al. Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey. I. Illustrative reference ranges by age, sex and hormone use. Br J Haematol 1997;97:775–84.

[117] Aihara K, Azuma H, Takamori N, et al. Heparin cofactor II is a novel protective factor against carotid atherosclerosis in elderly individuals. Circulation 2004;109:2761–5.

[118] Halle BM, Poulsen TD, Pedersen HP. Indocyanine green plasma disappearance rate as dynamic liver function test in critically ill patients. Acta Anaesth Scand 2014;58:1214–9.

[119] Mullerhocker J, Aust D, Rohrbach H, et al. Defects of the respiratory chain in the normal human liver and in cirrhosis during aging. Hepatology 1997;26:709–19.

[120] Modi HR, Katyare SS, Patel MA. Ageing-induced alterations in lipid/phospholipid profiles of rat brain and liver mitochondria: implications for mitochondrial energy-linked functions. J Membr Biol 2008;221:51–60.

[121] Navarro A, Boveris A. Rat brain and liver mitochondria develop oxidative stress and lose enzymatic activities on aging. Am J Physiol-Reg I 2004;287:R1244–R9.

[122] Brown-Borg HM, Johnson WT, Rakoczy SG. Expression of oxidative phosphorylation components in mitochondria of long-living Ames dwarf mice. Age 2012;34:43–57.

[123] Sastre J, Pallardo FV, Pla R, et al. Aging of the liver: age-associated mitochondrial damage in intact hepatocytes. Hepatology 1996;24:1199–205.

[124] Serviddio G, Bellanti F, Romano AD, et al. Bioenergetics in aging: mitochondrial proton leak in aging rat liver, kidney and heart. Redox Rep 2007;12:91–5.

[125] Hagen TM, Yowe DL, Bartholomew JC, et al. Mitochondrial decay in hepatocytes from old rats: membrane potential declines, heterogeneity and oxidants increase. Proc Natl Acad Sci USA 1997;94:3064–9.

[126] Garcia-Fernandez M, Sierra I, Puche JE, et al. Liver mitochondrial dysfunction is reverted by insulin-like growth factor II (IGF-II) in aging rats. J Transl Med 2011;9:123.

[127] Maes OC, An J, Sarojini H, et al. Murine microRNAs implicated in liver functions and aging process. Mech Ageing Dev 2008;129:534–41.

[128] Capri M, Olivieri F, Lanzarini C, et al. Identification of miR-31-5p, miR-141-3p, miR-200c-3p, and GLT1 as human liver aging markers sensitive to donor-recipient age-mismatch in transplants. Aging Cell 2017;16:262–72.

[129] Shenvi SV, Smith E, Hagen TM. Identification of age-specific Nrf2 binding to a novel antioxidant response element locus in the Gclc promoter: a compensatory means for the loss of glutathione synthetic capacity in the aging rat liver? Aging Cell 2012;11:297–304.

[130] Kwekel JC, Desai VG, Moland CL, et al. Age and sex dependent changes in liver gene expression during the life cycle of the rat. BMC Genomics 2010;11:675.

[131] Dejong EN, Surette MG, Bowdish DME. The gut microbiota and unhealthy aging: disentangling cause from consequence. Cell Host Microbe 2020;28:180–9.

[132] Malaguarnera G, Giordano M, Nunnari G, et al. Gut microbiota in alcoholic liver disease: pathogenetic role and therapeutic perspectives. World J Gastroenterol 2014;20:16639–48.

[133] Santoro A, Ostan R, Candela M, et al. Gut microbiota changes in the extreme decades of human life: a focus on centenarians. Cell Mol Life Sci 2018;75:129–48.

[134] Franceschi C, Garagnani P, Parini P, et al. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol 2018;14:576–90.

[135] Le Couteur DG, Mclean AJ. The aging liver. Drug clearance and an oxygen diffusion barrier hypothesis. Clin Pharmacokinet 1998;34:359–73.

[136] Wynne HA, Cope LH, Mutch E, et al. The effect of age upon liver volume and apparent liver blood-flow in healthy man. Hepatology 1989;9:297–301.

[137] Wakabayashi H, Nishiyama Y, Ushiyama T, et al. Evaluation of the effect of age on functioning hepatocyte mass and liver blood flow using liver scintigraphy in preoperative estimations for surgical patients: comparison with CT volumetry. J Surg Res 2002;106:246–53.

[138] Stahl EC, Haschak MJ, Popović B, et al. Macrophages in the aging liver and age-related liver disease. Front Immunol 2018;9:2795.

[139] Zoli M, Magalotti D, Bianchi G, et al. Total and functional hepatic blood flow decrease in parallel with ageing. Age Ageing 1999;28:29–33.

[140] Zoli M, Iervese T, Abbati S, et al. Portal blood velocity and flow in aging man. Gerontology 1989;35:61–5.

[141] Moon CM, Kim SK, Heo S, et al. Hemodynamic changes in the portal vein with age: evaluation using four-dimensional flow MRI. Sci Rep-Uk 2023;13:7397.

[142] Pasquinelli F, Belli G, Mazzoni LN, et al. Magnetic resonance diffusion-weighted imaging: quantitative evaluation of age-related changes in healthy liver parenchyma. Magn Reson Imaging 2011;29:805–12.

[143] Huang H, Zheng CJ, Wang LF, et al. Age and gender dependence of liver diffusion parameters and the possibility that intravoxel incoherent motion modeling of the perfusion component is constrained by the diffusion component. NMR Biomed 2021;34:e4449.

[144] Kuhn JP, Meffert P, Heske C, et al. Prevalence of fatty liver disease and hepatic iron overload in a Northeastern German Population by using quantitative MR imaging. Radiology 2017;284:706–16.

[145] Singh S, Venkatesh SK, Wang Z, et al. Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data. Clin Gastroenterol Hepatol 2015;13:440–451.e6.

[146] Zhao F, Zhou N, Wang JL, et al. Collagen deposition in the liver is strongly and positively associated with T1rho elongation while fat deposition is associated with T1rho shortening: an experimental study of methionine and choline-deficient (MCD) diet rat model. Quant Imag Med Surg 2020;10:W2307–21.

[147] Cao Y, Zhou K, Diao W, et al. Age-related changes of standardized uptake values in the blood pool and liver: a decade-long retrospective study of the outcomes of 2,526 subjects. Quant Imag Med Surg 2021;11:95–106.

[148] Meier JM, Alavi A, Iruvuri S, et al. Assessment of age-related changes in abdominal organ structure and function with computed tomography and positron emission tomography. Semin Nucl Med 2007;37:154–72.

[149] Anantharaju A, Feller A, Chedid A. Aging liver: a review. Gerontology 2002;48:343–53.

[150] Miller NE. Why does plasma low density lipoprotein concentration in adults increase with age?. Lancet 1984;323:263–7.

[151] Maeso-Díaz R, Ortega-Ribera M, Fernández-Iglesias A, et al. Effects of aging on liver microcirculatory function and sinusoidal phenotype. Aging Cell 2018;17:e12829.

[152] Wan J, Wu X, Chen H, et al. Aging-induced aberrant RAGE/PPARα axis promotes hepatic steatosis via dysfunctional mitochondrial β oxidation. Aging Cell 2020;19:e13238.

[153] Gee JR, Ding Q, Keller JN. Modulation of apolipoprotein E and interleukin-1β in the aging liver. Exp Gerontol 2005;40:409–15.

[154] Zhao H, Ji Q, Wu Z, et al. Destabilizing heterochromatin by APOE mediates senescence. Nat Aging 2022;2:303–16.

[155] Li J, Xiong M, Fu X-H, et al. Determining a multimodal aging clock in a cohort of Chinese women. Med 2023;4:825–48.

[156] Huang Y-L, Shen Z-Q, Huang C-H, et al. Cisd2 slows down liver aging and attenuates age-related metabolic dysfunction in male mice. Aging Cell 2021;20:e13523.

[157] Le Couteur DG, Blyth FM, Creasey HM, et al. The association of alanine transaminase with aging, frailty, and mortality. J Gerontol 2010;65A:712–7.

[158] Puzianowska-Kuźnicka M, Owczarz M, Wieczorowska-Tobis K, et al. Interleukin-6 and C-reactive protein, successful aging, and mortality: the PolSenior study. Immun Ageing 2016;13:21.

[159] Paik JK, Chae JS, Kang R, et al. Effect of age on atherogenicity of LDL and inflammatory markers in healthy women. Nutr Metab Cardiovasc Dis 2013;23:967–72.

[160] Lassale C, Batty GD, Steptoe A, et al. Association of 10-year C-reactive protein trajectories with markers of healthy aging: findings from the English Longitudinal Study of aging. J Gerontol A Biol Sci Med Sci 2019;74:195–203.

[161] Tang Y, Liang P, Chen J, et al. The baseline levels and risk factors for high-sensitive C-reactive protein in Chinese healthy population. Immun Ageing 2018;15:21.

[162] Maggio M, Ble A, Ceda GP, et al. Decline in insulin-like growth factor-i levels across adult life span in two large population studies. J Gerontol: Series A 2006;61:182–3.

[163] Landin-Wllhelmsen K, Wllhelmsen L, Lappast G, et al. Serum insulin-like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin. Clin Endocrinol 1994;41:351–7.

[164] Goodman-Gruen D, Barrett-Connor E. Epidemiology of insulin-like growth factor-I in elderly men and women: the Rancho Bernardo Study. Am J Epidemiol 1997;145:970–6.

[165] Heart Failure Group of Chinese Society of Cardiology, Editorial Board of Chinese Journal of Cardiology, Zhang S, et al. Chinese expert consensus on the diagnosis and treatment of transthyretin cardiac amyoidosis. Zhonghua Xin Xue Guan Bing Za Zhi 2021;49:324–32 (in Chinese).

[166] Yasmin MY, Aziz B, Nazim M, et al. Prealbumin rather than albumin is a more sensitive indicator of acute liver disease. Malays J Pathol 1993;15:147–50.

[167] Gómez-Santos B, Saenz De Urturi D, NUñEZ-García M, et al. Liver osteopontin is required to prevent the progression of age-related nonalcoholic fatty liver disease. Aging Cell 2020;19:e13183.

[168] Sousa-Victor P, Neves J, Cedron-Craft W, et al. MANF regulates metabolic and immune homeostasis in ageing and protects against liver damage. Nat Metab 2019;1:276–90.

[169] Wang S, Hu M, Qian Y, et al. CHI3L1 in the pathophysiology and diagnosis of liver diseases. Biomed Pharmacother 2020;131:110680.

[170] Zabransky DJ, Jaffee EM, Weeraratna AT. Shared genetic and epigenetic changes link aging and cancer. Trends Cell Biol 2022;32:338–50.

[171] Kaji K, Factor V, Andersen J, et al. DNMT1 is a required genomic regulator for Murine liver histogenesis and regeneration. Hepatology 2016:64:582–98.

[172] Bysani M, Perfilyev A, De Mello VD, et al. Epigenetic alterations in blood mirror age-associated DNA methylation and gene expression changes in human liver. Epigenomics 2017;9:105–22.

[173] Tian YE, Cropley V, Maier AB, et al. Heterogeneous aging across multiple organ systems and prediction of chronic disease and mortality. Nat Med 2023;29:1221–31.

[174] Le Goallec A, Diai S, Collin S, et al. Using deep learning to predict abdominal age from liver and pancreas magnetic resonance images. Nat Commun 2022;13:1979.

[175] Radonjić T, Dukić M, Jovanović I, et al. Aging of liver in its different diseases. Int J Mol Sci 2022;23:13085.

RIGHTS & PERMISSIONS

2024 The Author(s) 2024. Published by Oxford University Press on behalf of Higher Education Press.